التفاصيل البيبلوغرافية
| العنوان: |
Safety and Efficacy of Nivolumab in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study |
| المؤلفون: |
Vogelzang, Nicholas J., Olsen, Mark R., McFarlane, Joshua J., Arrowsmith, Edward, Bauer, Todd M., Jain, Rohit K., Somer, Bradley, Lam, Elaine T., Kochenderfer, Mark D., Molina, Ana, Doshi, Gurjyot, Lingerfelt, Brian, Hauke, Ralph J., Gunuganti, Vijay, Schnadig, Ian, Van Veldhuizen, Peter, Fleming, Mark, Galamaga, Robert, Gupta, Mukul, Hool, Hugo, Hutson, Thomas, Zhang, Joshua, McHenry, M. Brent, Johansen, Jennifer L., Tykodi, Scott S. |
| المصدر: |
Clinical Genitourinary Cancer; December 2020, Vol. 18 Issue: 6 p461-468.e3 |
| مستخلص: |
The open-label phase IIIb/IV CheckMate 374 study (NCT02596035) was conducted to validate the safety and efficacy of flat-dose nivolumab 240 mg every 2 weeks (Q2W) in previously treated advanced/metastatic renal cell carcinoma. Three cohorts included patients with predominantly clear cell histology, non–clear cell histologies, or brain metastases. We report safety and efficacy from the advanced non–clear cell RCC (nccRCC) cohort of CheckMate 374. |
| قاعدة البيانات: |
Supplemental Index |
